免疫检查点阻断疗法及其联用策略  

Combination strategies with immune-checkpoint blockade in cancer therapy

作　　者：赵雪梅 韩秋菊[1] 张建[1] ZHAO Xue-Mei;HAN Qiu-Ju;ZHANG Jian(Institute of Immunopharmaceutical Sciences,School of Pharmaceutical Sciences,Shandong University,Jinan 250012,China)

机构地区：[1]山东大学药学院免疫药物学研究所

出　　处：《中国免疫学杂志》2019年第13期1651-1655,1661,共6页Chinese Journal of Immunology

基　　金：山东省重点研发项目(2017GSF18159);山东省自然基金(ZR2017BH029);山东大学基本科研业务项目(2017JC004)资助

摘　　要：免疫检查点阻断(ICB)是激活抗肿瘤免疫的有效策略之一,在多种恶性肿瘤的治疗中取得了显著成效,具有广阔的应用前景。然而,临床治疗结果表明,仅有少数患者可以产生有效应答,而且部分患者在后续的治疗中产生耐药现象。因此,免疫检查点阻断疗法与传统放化疗、肿瘤靶向治疗以及新型细胞免疫治疗的联合应用策略,在克服耐药以及拓展免疫检查点治疗临床应用等方面具有重大意义。Immune checkpoint blockade (ICB) is one of the effective strategies for activating anti-tumor immunity.It has achieved remarkable results in the treatment of various malignant tumors and has broad application prospects.However,clinical treatment results indicate that only a small number of patients show an effective response,and some patients develop resistance in subsequent treatment.Therefore,the combination of immunological checkpoint block therapy with traditional radiotherapy and chemotherapy,tumor targeted therapy and new cellular immunotherapy has great significance in overcoming drug resistance and expanding the clinical application of immune checkpoint treatment.

关 键 词：肿瘤 免疫检查点阻断 耐药 联用策略 

分 类 号：R730.51[医药卫生—肿瘤]